Exploring High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has seen a decline of 4.1%, yet it remains up by 21% over the past year with earnings projected to grow by 18% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that not only demonstrate robust innovation and scalability but also have strong fundamentals to navigate current market fluctuations.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 70 stocks from our US High Growth Tech and AI Stocks screener.

We’ll examine a selection from our screener results.

Simply Wall St Growth Rating: ★★★★★☆

Overview: LightPath Technologies, Inc. is a company that designs, develops, manufactures, and distributes optical systems and assemblies in the United States with a market capitalization of $883.45 million.

Operations: LightPath Technologies focuses on the optics segment, generating $62.77 million from designing and manufacturing optical products.

Despite recent financial struggles, LightPath Technologies shows potential for significant growth, evidenced by a forecasted annual revenue increase of 36.2% and an impressive expected earnings growth rate of 122.64%. The company’s commitment to innovation is underscored by its substantial R&D efforts, which have recently been bolstered by a follow-on equity offering raising nearly $100 million. This infusion is likely aimed at fueling further technological advancements and market expansion. While the share price has been volatile, these strategic moves could position LightPath favorably in the high-tech optics sector as it moves towards profitability in the coming years.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Intellia Therapeutics, Inc. is a clinical-stage genome editing company that develops potentially curative therapeutics using CRISPR/Cas9-based technologies, with a market cap of $1.80 billion.

Operations: Intellia Therapeutics focuses on the development of gene editing-based therapies, generating $66.09 million in revenue from this segment.

Intellia Therapeutics, a frontrunner in the CRISPR gene-editing space, has demonstrated resilience with a narrowed net loss of $96.23 million from $114.33 million year-over-year and an improved basic loss per share to $0.81 from $1.1. This improvement aligns with its aggressive R&D focus, highlighted by its recent follow-on equity offering which raised $180 million to advance projects like lonvo-z for hereditary angioedema (HAE). The potential of lonvo-z is underscored by positive Phase 3 trial results and multiple regulatory nods, setting the stage for a transformative impact in HAE treatment and possibly boosting Intellia’s financial trajectory as it moves towards commercialization expected in early 2027.

Simply Wall St Growth Rating: ★★★★★★

Overview: AppLovin Corporation offers comprehensive AI-driven advertising solutions for businesses globally, with a market capitalization of $174.97 billion.

Operations: The company generates revenue primarily through its advertising segment, which brought in $6.16 billion.

AppLovin’s recent performance underscores its robust position in the tech landscape, with a notable first-quarter sales surge to $1.84 billion from $1.16 billion year-over-year and a doubling of net income to $1.21 billion. This growth trajectory is complemented by an aggressive R&D investment strategy, crucial for sustaining innovation and competitive edge in the rapidly evolving tech sector. Moreover, the company’s strategic share repurchases, which saw 2.17 million shares bought back for approximately $1 billion in the first quarter alone, reflect a strong commitment to shareholder value and confidence in its financial health. These factors collectively highlight AppLovin’s potential as a dynamic player within high-growth technology markets.

Where To Now?

• Dive into all 70 of the US High Growth Tech and AI Stocks we have identified here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com